MEDIPOST Co., Ltd. announced a private placement of series 9 registered non-guaranteed private placement convertible bonds for a gross proceeds of KRW 35,000,000,000, series 8th bearer type non-guaranteed private placement bond for proceeds of KRW 35,000,000,000 and 3,740,314 convertible preferred stock with registered voting rights at a price of KRW 18,715 for a gross proceeds of KRW 69,999,976,510; for aggregate gross proceeds of KRW 139,999,976,510 on March 16, 2022. The transaction will include participation from Marvel 2022 Holdings Ltd. for KRW 31,756,000,000, and Crescendo 3rd Euiho Private Equity Joint Venture Company for KRW 3,244,000,000. The series 9 and series 8 bonds have a coupon rate of 0%, and yield to maturity of 2%. The series 9 bonds will mature on April 08, 2029 and series 8 bonds will mature on March 28, 2029. The bonds will be 100% converted into 1,776,649 common shares at a fixed conversion price of KRW 19,700 per share for an equity stake of 10.9%. The conversion period of series 9 bonds is from April 08, 2022 to March 08, 2029 series 8 bonds is from March 28, 2023 to February 28, 2029. The company will issue shares of par value of KRW 500 per share through third party allocation method. The payment date of series 9 convertible bonds is April 08, 2022 and series 8 bonds is March 28, 2022 and for convertible preferred stock is June 30, 2022. The securities issued in the transaction are subject to a lock up period of one year. The transaction has been approved by the board of directors of the company.

On March 25, 2022, the company announced that it will issue series 9 non-guaranteed private convertible bonds in the transaction.